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Background: The effects of inhaled steroids upon the quality of life of patients with
bronchiectasis remain unknown.
Study objective: To analyze the effect of inhaled fluticasone propionate (FP) for 6
months upon the clinical, functional, microbiological and outcome parameters of
patients with steady-state bronchiectasis not due to cystic fibrosis, and its
repercussions for patient health-related quality of life (HRQoL).
Design: Prospective, randomized, double-blind (for effective doses) study.
Patients and interventions: The diagnosis of bronchiectasis was made by high-
resolution computed tomography. Ninety-three patients (mean age: 68.5 [8.4]) were
randomized to receive 250mg bid, 500mg bid or no treatment with inhaled FP for 6
months. Data were collected at baseline and at 1, 3 and 6 months after the start of
treatment. HRQoL was assessed using the validated Spanish version of the St. George’s
Respiratory Questionnaire.
Results: The group administered FP 1000 mg daily showed significant improvement
in dyspnea (1.03 [2.1]1.24 [2.2] points; P ¼ 0:0120:04), sputum production
(P ¼ 0:001), days without cough (P ¼ 0:02) and short-acting beta-2 agonists used
(P ¼ 0:01) from the first month of treatment, with no changes in pulmonary function,
number or severity of exacerbations, or microbiological profile of the sputum. As a
result, an improvement in HRQoL was seen in this group after 3 months of treatment
(45.4 [14.2] vs. 40.5 [13.9]; P ¼ 0:01).Elsevier Ltd. All rights reserved.
eumologı´a, Servicio de Medicina Interna, Hospital General de Requena, Paraje Casa Blanca s/n,
+34 96 2336972; fax: +34 96 2336973.
.es (M.A. Martı´nez-Garcı´a).
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M.A. Martı´nez-Garcı´a et al.1624Conclusions: Inhalatory FP 500 mg bid is effective from the first month of treatment
for controlling the symptoms of patients with steady-state bronchiectasis—thus
ensuring a significant improvement in HRQoL.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Bronchiectasis is a chronic airways disease char-
acterized by progressive dilation and destruction of
the bronchial tree.1 As a result of the associated
dysfunction of mucociliary clearance, a vicious
circle is established involving persistent bacterial
colonization, chronic inflammation of the bronchial
mucosa, and progressive tissue destruction.2 Stu-
dies of bronchial biopsies in patients with bronch-
iectasis have shown a significant acute and chronic
inflammatory component involving mainly neutro-
phils and abundant CD4+ and CD8+T lymphocyte.
3,4
On the other hand, sputum analysis usually shows a
large variety of cell secretion products (interleu-
kin-8, interleukin-6 and tumor necrosis factor-a),5,6
and enzymes such as elastases and neutrophil
peroxidases.7
Bronchiectasis is associated with chronic and
frequently purulent expectoration, multiple ex-
acerbations, impaired lung function usually com-
prising chronic airflow obstruction with eventual
bronchial hyperresponsiveness and the appearance,
in advanced stages, of progressive dyspnea that can
become disabling.8 These alterations gradually
worsen the health-related quality of life (HRQoL)
of these patients.9,10
Very few studies have analyzed the effect of
inhaled steroids upon the treatment of patients
with steady-state bronchiectasis.11–13 It seems to
be well established that high doses of inhaled
steroids afford some improvement of certain
clinical parameters, without changes in lung func-
tion or in the number of exacerbations, among
patients with bronchiectasis.11 However, some
important variables remain to be examined in this
sense, such as the influence of different inhaled
steroids doses (including their possible adverse
effects) or the effect of this treatment upon
patient HRQoL. This has led the Cochrane Colla-
boration14 in an updated review of the subject, to
stress the need for new studies in this field. We
hypothesized that treatment with inhaled steroids
in patients with steady-state bronchiectasis affords
significant improvement in HRQoL fundamentally as
a result of better clinical control.
The present study analyzes the effect of inhaled
fluticasone propionate (FP) for 6 months upon the
clinical, functional, microbiological and outcomeparameters of patients with steady-state bronch-
iectasis not due to cystic fibrosis (CF), and its
repercussions for patient HRQoL.Materials and methods
Patient selection
The study initially included all patients with
bronchiectasis affecting more than one pulmonary
lobe or cystic bronchiectasis (localized or other-
wise) not due to CF and diagnosed in our center
between 1993 and June 2003. The patients were
required to be clinically stable, i.e., free
from acute exacerbations for at least 4 weeks.
Exacerbation was defined as persistent (424 h)
deterioration of at least three respiratory symp-
toms (including cough, dyspnea, hemoptysis, in-
creased sputum purulence or volume, and chest
pain) with or without fever, radiographic deteriora-
tion, systemic involvement, or deterioration in
chest signs.13 The study excluded patients with
possible asthma according to the definition of the
Global Initiative for Asthma (GINA)15; patients with
allergic bronchopulmonary aspergillosis according
to previously described diagnostic criteria16; those
unable to comply with the study protocol because
of serious and unstable physical or psychiatric
disorder; patients previously exposed to long-term
oral steroid therapy or other immunosuppressants;
and patients in whom prior inhaled steroid treat-
ment (if any) could not be discontinued. Patients
with suspected chronic obstructive pulmonary
disease (COPD) were not excluded from the study,
though we stratified randomization of the treat-
ment groups according to smoking habit as mea-
sured in pack-years. The study was approved by the
local ethics committee, and all patients gave
informed consent to participation in the study.
Diagnosis of bronchiectasis
The diagnosis of bronchiectasis was established in
all cases by high-resolution computed tomography
(HRCT) of the chest with 1–1.5mm sections every
10mm and subsequent reconstruction following the
criteria described by Naidich et al.17 HRCT was
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Inhaled steroids in bronchiectasis 1625performed a maximum of 24 months prior to the
start of the study. In the event diagnostic HRCTwas
performed at an earlier date, the exploration was
repeated to update the diagnosis and the extent of
bronchiectasis. To assess the presence and extent
of bronchiectasis, the modified Bhalla score was
used.18 HRCTwas interpreted by a radiologist and a
clinician independently.Study design
A prospective, randomized (stratified for prior
smoking habit in pack-years), double-blind (only
for effective doses) study was designed, comprising
three groups of patients assigned to the following
treatments for 6 months: no inhaled steroid
treatment (Group 0 F), 250 mg bid (Group 500 F)
or 500 mg bid (Group 1000 F) of inhaled FP
(metered-dose inhaler) through a Volumatics
chamber for the purpose of analyzing the effect
of treatment on various clinical, functional, micro-
biological and outcome variables, and its influence
upon HRQoL. All patients were previously in-
structed by qualified staff on the proper use of
the inhalers. The study was conducted on a double
blind basis regarding the effective inhalatory
steroid dose administered (500 vs. 1000 mg/day),
but not as relates to the administration or not of
steroid treatment (i.e., 0 vs. 500 or 1000 mg/day).
A complete clinical history was obtained in all
patients, including information on their past
medical history and details of their smoking habit.
Patients who prior to starting the study were using
long-term inhaled steroids for bronchiectasis were
scheduled for three visits at 1-month intervals in
the 3 months prior to randomization, in order to
progressively reduce the steroid dose to disconti-
nuation. On each visit, the dose of the previous
visit was halved, discontinuing inhaled steroids on
the third visit, controlling possible changes in
patient clinical parameters or pulmonary function,
and optimizing bronchodilator treatment in all
cases. The patients were allowed to continue using
their other regular treatments. After the inhaled
steroids were completely removed, a 3-month
washout period was completed before randomiza-
tion was carried out.Measurements
In all cases, baseline data collection started during
the 6 months prior to randomization. In this period
prospective information was obtained regarding
the number of acute exacerbations, antibiotic use,
cycles of oral steroids, and hospital admissions orvisits to emergency rooms. During the randomiza-
tion visit, the following tests were performed:
(a) assessment of baseline dyspnea based on the
baseline dyspnea index (BDI),19 (b) retrieval of a
symptoms in which the patients had recorded the
number of days with cough or wheezing, and the
number of inhalations of rescue short-acting b2
agonists used in the month prior to randomization;
(c) measurement of the mean amount of sputum
produced daily (in ml). This was evaluated by
instructing the patients to collect the amount of
sputum during the 3 days prior to randomization in
three graded sterile containers (one per day), and
marking the amount reached each day on the
container. Instructions were given to ensure that
sputum collection was as correct as possible—the
percentage saliva recorded being the lowest
possible. The average of the three measurements
was taken to be the valid sputum output;
(d) assessment of HRQoL using the validated
Spanish version of the St. George’s Respiratory
Questionnaire (SGRQ).20
On the other hand, three pairs of fresh sputum
samples were collected in the 6 months prior to
randomization, with 1 month between each pair of
samples, for microbiological testing—including
gram staining and culture in standard media or
special media in the case of a clinically suspected
specific microorganism. In valid sputum (o10
epithelial cells and 425 leukocytes/field),21
chronic colonization was considered when the
microorganism appeared as over 1 105 CFU/ml at
least in three sputum samples corresponding to
different visits outside an acute exacerbation
period. During the days prior to randomization,
the following pulmonary function measurements
were made; forced spirometry measuring the
forced expiratory volume in 1 s (FEV1) and forced
vital capacity (FVC),22 and the FEV1 and FVC values
15min after the inhalation of 200 mg of salbutamol.
Total lung capacity (TLC) and residual volume (RV)
were measured by the helium dilution technique
and indexes of gas transfer were measured using a
carbon monoxide single-breath test adjusted for
alveolar volume (KCO); gas transfer results were
adjusted for hemoglobin. All maneuvers were
performed by qualified staff and at the same time
in the morning.
After randomization, TLC, RV and KCO were
analyzed again after 6 months of treatment. HRQoL
assessment and the microbiological analysis of
sputum were carried out after 3 and 6 months of
treatment. Changes of over 4 points in the SGRQ
were considered to be clinically significant.23 The
other tests described, and the appearance of side
effects, were assessed at 1, 3, and 6 months in all
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M.A. Martı´nez-Garcı´a et al.1626three groups of treatment. Dyspnea was assessed
by the transition dyspnea index (TDI),24 where
changes of over 1 point were considered to be
clinically significant.Statistical analysis
All data were showed as the mean and standard
deviation (SD) in the case of quantitative variables
and as absolute values and percentages in the case
of qualitative variables. The principal study vari-
able was taken to be a clinically significant change
(X4 points) in SGRQ total score. We calculated that
a sample size of 75 patients (25 per treatment
group for comparing three repeated means) was
required to detect a significant change in SGRQ
total score with 80% power and 0.05 alpha-level
test, assuming a maximum patient loss of 20% in the
course of the study. The normality of all variables
was verified by the Kolmogorov–Smirnov test. In the
event of a non-normal distribution, log-transforma-
tion was carried out. This proved necessary for the
variables referring to the number of acute exacer-
bations, cycles of steroids, oral antibiotics, or the
number of visits to emergency rooms or hospital
admissions. For the intergroup comparison of
baseline data, a one-way analysis of variance
(ANOVA) with Bonferroni correction was used in
the case of quantitative variables, and the Fried-
man’s test in the case of qualitative variables. For
the intra- and intergroup comparison of variables
during the study, a repeated-measure ANOVA wasEligible patients
(n=132)
Patients randomized
(n=93)
0 µg FP day
(n=31)
250 µg FP bid
(n=31)
Complete study
(n=28) Complete study(n=29)
Withdrawn throughout
the study (n=3) Withdrawn ththe study (n=
-Non-compliance (n=1)
- Failure to return (n=2)
-No inh steri
-Death (n=1)
Figure 1 Profile of number of paused. Calculations were also made of the minimum
number needed to treat (NNT) to obtain a clinically
significant change in the variables for which
statistically significant changes were recorded
(Po0:05) with steroid treatment.25Results
Patient demographics
Of the 132 patients initially included in the study,
39 were excluded prior to randomization. The most
frequent cause of exclusion was the presence of a
high clinical probability of bronchial asthma
(n ¼ 23). Ninety-three patients were therefore
finally randomized. During the study, 7 additional
patients were excluded (Fig. 1). Thus, 86 patients
completed the study (28 in Group 0 F; 29 in Group
500 F and 29 in Group 1000 F). Table 1 shows
the baseline characteristics of the three groups.
Significant pre-randomization differences were
only seen in the number of patients colonized
by Haemophilus influenzae (HI), which was lower
in Group 500 F (7%, P ¼ 0:018). Eighteen patients
were using inhaled steroids prior to the start of the
study. All but one of these individuals were able to
completely discontinue inhalatory medication and
completed the 3-month washout period prior to
randomization. There were no significant differ-
ences among the three study groups in terms of the
number of individuals using inhaled steroids prior to
the start of the study.500 µg FP bid
(n=31)
Patients withdrawn before
randomisation (n=39; 28.1%)
-High probability of asthma  23
-No consent                           4
-Down synd.                           1
-Psychiatric dis.                      3
-Systemic steroids                  3
-Significant severity                 3
Complete study
(n=29)
roughout
2)
Withdrawn throughout
the study (n=2)
ods (n=1) -Non-compliance (n=1)
-Adverse event (n=1)
tients throughout the study.
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Table 1 Demographics and baseline characteristics of the randomized patients who completed the study.
Variables 0 mg/d Fluti (n ¼ 28) 500 mg/d Fluti (n ¼ 29) 1000 mg/d Fluti (n ¼ 29)
Age, yr 70.9 (6.1) 66.4 (12.6) 70.9 (6)
Gender (% males) 61 62 72
HRCT score 4.1 (2,3) 4.3 (2.2) 4.8 (2.5)
24-h sputum production (ml) 21.9 (23.1) 21.1 (24.8) 22.1 (14.7)
Smoking, pack-yr 37.3 (32) 35.1 (30.2) 36.8 (29.1)
BDI focal score 6.41 (2.6) 6.54 (2.6) 6.5 (3.1)
Short-acting b2/week use 5.5 (4.1) 5.89 (4.5) 5 (4.7)
Long-acting b2 (%) 68 76 72
Anticholinergics (%) 25 28 34
FEV1, L 1405 (546) 1421 (567) 1384 (577)
FEV1% predicted 62.3 (17.7) 61.7 (20.3) 59.8 (23,5)
FVC, L 2227 (719) 2357 (766) 2478 (727)
FVC, % predicted 74.8 (18.4) 78.9 (14.9) 79.3 (15.9)
Positive BDT (%) 21 17 17
Pseudomonas colonization (%) 21 17 24
H. influenzae colonization (%) 38 7 21
No. of exacerbations 1.17 (1.3) 1.29 (1.7) 1.14 (1.1)
No. of hospital admissions 0.07 (0.3) 0.07 (0.3) 0.03 (0.2)
Total SGRQ score 45.5 (15.1) 45.2 (11.8) 45.5 (14.2)
Symptoms SGRQ score 45.3 (13.7) 45.6 (12.8) 45.3 (14.9)
Activity SGRQ score 51.6 (16.9) 51.8 (12.5) 53.2 (14.7)
Impact SGRQ score 40.3 (14.3) 38.5 (10.9) 40.8 (13.3)
Quantitative variables are tabulated as mean and standard deviation. Qualitative variable are tabulated as percentage.
HRCT: High-resolution computed tomography; BDI: Basal dyspnea index; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital
capacity; TBD; Bronchodilator test.
P ¼ 0:018 for 500 F vs. 0 F.
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Inhaled steroids in bronchiectasis 1627Changes in pulmonary function
There were no significant changes from baseline in
any of the three treatment groups for any of the
functional variables analyzed during the 6 months
of the study. Reductions of 62 (181) and 39 (147)ml
were found in FVC in Groups 0 F and 500 F,
respectively, and an increase of 25 (104)ml in
Group 1000 F at 6 months of treatment. Group 1000
F showed a non-significant improvement in FEV1
that was more marked during the first month of
treatment (+38 [145]ml) and reached +64 (154)ml
vs. baseline after 6 months. No such improvement
was seen in any of the other two groups (11
[93]ml and 38 [107]ml for Groups 500 F and 0 F,
respectively, at 6 months of treatment) (Fig. 2).Figure 2 Changes in the absolute FEV1 value in the three
treatment groups along the 6 months of the study from
baseline.Dyspnea
All three treatment groups showed improvement in
dyspnea (TDI), though clinical significance was only
observed in Group 1000 F at 1 month of treatment
(+1.03 [2.1] points; P ¼ 0:04); this improvement
persisted after 3 months (+1.28 [2.3] points;
P ¼ 0:01) and 6 months (+1.24 [2.2] points;P ¼ 0:02) (Fig. 3). There were no statistically
significant differences between Groups 1000 F and
500 F, though in the course of the study the latter
group failed to reach the minimum improvement in
dyspnea defining clinical significance (1 point). The
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Figure 3 TDI values along the study in the three
treatment groups. The discontinuous line is the threshold
from which it is considered that there is a clinically
significant improvement in dyspnea. Threshold of clinical
significance. *P ¼ 0:04; **P ¼ 0:01; +P ¼ 0:02 for 1000 F
vs. 0 F at 1, 3 and 6 months after randomization,
respectively.
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Figure 4 Changes in the amount of sputum produced
daily in ml in the three treatment groups during the
study. *P ¼ 0:001 for 1000 F vs. baseline values.
**P ¼ 0:02 for 500 F vs. baseline values. +P ¼ 0:04 for
1000 F vs. 0 F at 1 and 6 months after randomization.
++P ¼ 0:01 for 1000 F vs. 0 F at 3 months after
randomization.
M.A. Martı´nez-Garcı´a et al.1628number (percentage) of patients improving over 1
point at 6 months of treatment was significantly
greater in Group 1000 F than in Group 0 F (19 [65.5%]
vs. 10 [34.5%], P ¼ 0:02). The NNT with FP 1000mg
was four patients (95% CI: 2–25) to obtain at least a
1-unit improvement in TDI score after 6 months of
treatment vs. the untreated group.Daily sputum production
At 1 month of treatment, a significant reduction
was observed in the volume of sputum from
baseline in Group 1000 F (9.7 [12.8]ml,
P ¼ 0:001) that persisted with minor variations
during the 6 months of study. A significant reduc-
tion also occurred in Group 500 F from baseline at 3
months of treatment (6.47 [12.5]ml; P ¼ 0:02),
though this effect decreased at 6 months (4.4
[17.3]ml, P ¼ 0:21) (Fig. 4). The intergroup study
revealed a significant decrease in the amount of
sputum produced in Group 1000 F vs. Group 0 F
from the first month of treatment (8.7 [11.3];
P ¼ 0:04), and this situation persisted after both 3
(10.7 [12.8]; P ¼ 0:01) and 6 months (8.3 [11.1];
P ¼ 0:04). Fourteen patients treated with 1000 F
(48.3%) had a reduction of over 50% in the amount
of sputum at 6 months, as compared to 11 patients
(37.9%) in Group 500 F (P ¼ 0:03) and 3 (10.7%) in
the untreated group (P ¼ 0:009). The NNT was two
patients (95% CI: 2–5) to obtain a reduction of 50%
in the amount of sputum daily at 6 months of
treatment with FP 1000 mg.Days without cough and wheezing
Regular coughing (450% of days) was recorded in
13 (46%), 12 (41%) and 13 (45%) of the patients in
Groups 0 F, 500 F and 1000 F, respectively. A
significant reduction in the number of patients with
regular cough was only observed in Group 1000 F at
1 month of treatment (17% [5 patients],
P ¼ 0:02)—an effect that persisted at 6 months
(24% [7 patients], P ¼ 0:01). On the other hand,
9 [31%], 9 [32%] and 9 [31%] of the patients suffered
regular wheezing in Groups 0 F, 500 F and 1000 F,
respectively—without changes in the course of the
study.Need for short-acting b2 agonists
The three treatment groups reduced their weekly
need for short-acting b2 agonists, though this
reduction was only significant in Group 1000 F at
1 month of treatment vs. baseline (3.34 [3.4] vs.
5.03 [4.7]; P ¼ 0:01)—a difference that persisted
throughout the study (3.45 [3.5]; P ¼ 0:01 and 2.72
[3.7]; P ¼ 0:01 vs. baseline at 3 and 6 months,
respectively)—and in Group 500 F at 6 months of
treatment vs. baseline (3.67 [3.8] vs. 5.89 [4.5];
P ¼ 0:03). After 6 months of treatment there were
significant differences between 0 F and 1000 F
(5.11 [3.8] vs. 2.72 [3.7]; P ¼ 0:01). The differ-
ences between groups 500 F and 1000 F failed to
reach statistical significance.
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There were no significant differences in the number
of acute exacerbations comparing those calculated
6 months before and after randomization (1.2 [1.1]
vs. 1.4 [1.3]; P ¼ 0:89 in Group 1000 F), or in the
administration of cycles of antibiotics, cycles of
oral steroids, visits to emergency rooms or hospital
admissions for acute worsening of any respiratory
condition in any of the three treatment groups.
Sputum microbiology
No significant changes were seen in the number
(percentage) of chronic colonizations by HI
(9 [32%], 4 [14%] and 8 [28%] in groups 0 F, 500 F,
1000 F, respectively, at 6 months) or Pseudomonas
aeruginosa (PA) (5 [18%], 4 [14%] and 7 [24%] in
groups 0 F, 500 F and 1000 F, respectively, at 6
months) in the three groups during the study vs. the
pre-randomization percentages.
Adverse events
A global analysis showed adverse events to be more
frequent in Group 1000 F vs. 500 F (19 vs. 7;
P ¼ 0:04). The most common problems were dry
mouth (8 patients), local irritation (n ¼ 4) and
transient dysphonia (n ¼ 4). Other side effects in
Group 1000 F were aphthae (n ¼ 1) and sneezing
(n ¼ 1). Oral candidiasis was only seen in two
patients (one patient in Group 1000 F). All adverse
events were mild and did not lead to treatment
discontinuation, except for one patient in Group
1000 F who was removed from the study due
to edema of the face after using an inhaled
steroid. One death occurred in Group 500 F due
to respiratory failure unrelated to inhalatory
steroid use.
Changes in HRQoL
There were no significant pre-randomization differ-
ences among the three treatment groups as regards
the total SGRQ score or scores of the three scales.
There was clinically significant improvement (X4
points) in total SGRQ score from baseline in Group
1000 F at 3 months of treatment (45.5 [14.2] vs.
40.5 [13.9], P ¼ 0:01) that persisted at 6 months
(Fig. 5A). Statistically significant improvement in
this same group was observed at 3 and 6 months in
the symptoms score (45.3 [14.9] vs. 37.1 [13.7] and
45.3 [14.9] vs. 35.3 [13.8], respectively, P ¼ 0:005)
(Fig. 5B) and at 6 months on the activity scale (53.2
[14.7] vs. 47.1 [14.1]; P ¼ 0:02). There were nochanges on the impact scale (40.8 [13.3] at base-
line vs. 37.1 [12.7] at 6 months; P ¼ 0:11). The
number (percentage) of patients with clinically
significant improvement in HRQoL was statistically
greater in Group 1000 F at both three (2 [7.4%],
9 [31%] and 17 [58.6%] for groups 0 F, 500 F and
1000 F, respectively, P ¼ 0:003) and 6 months
(2 [7.4%], 10 [34.4%] and 15 [51.7%], respectively;
P ¼ 0:009) (Fig. 5C). The NNT was two patients
(95% CI: 2–4) to obtain clinically significant im-
provement with treatment in the form of 1000 FP
during 6 months.
Finally, an intent-to-treat analysis was carried
out including 90 out of 93 randomized patients
(29 in Group 0 F; 30 in Group 500 F, and 31 in Group
1000 F), since one patient died during the study and
two failed to return for the first visit after
randomization and could not be located. The
results did not differ significantly in the analysis
of any of the variables studied vs. the results
obtained in the group of 86 patients that completed
the study.Discussion
In our series, treatment with inhaled FP 500 mg bid
in patients with non-CF steady-state bronchiectasis
led to significant and early improvement (as soon as
after 1 month of treatment, and persisting for at
least 6 months) in daily sputum production,
dyspnea, days without cough, and number of doses
of short-acting b2 agonists required weekly. How-
ever, the parameters corresponding to microbiolo-
gical colonization of sputum, pulmonary function
and the number or severity of acute exacerbations
did not change. These results afforded significant
improvement in the HRQoL of these patients that
persisted during the 6 months of treatment.
Although the number of adverse events was
globally greater in Group 1000 F, they were local
and reversible.
In a recent study we found the parameters
exerting the greatest effect upon HRQoL in patients
with steady-state bronchiectasis to be dyspnea,
airflow obstruction and daily sputum production.10
In the present study, the significant clinical stability
recorded in the group administered inhaled
FP 1000 mg daily (attributable to minor improve-
ment in dyspnea and significant reduction in daily
sputum production) comprised clinically significant
and sustained HRQoL improvement during the
study. This parameter, which is fundamental given
its multidimensionality in the efficacy of any
therapeutic approach, had not been previously
analyzed with this regard in patients with non-CF
ARTICLE IN PRESS
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Figure 5 Changes in the HRQoL (SGRQ) during the study in the three treatment groups. (A) Changes in the total score.
(B) Changes in the scale of symptoms. (C) Percentage of patients with significant changes (74 points). *P ¼ 0:01 for
1000 F vs. baseline values. **P ¼ 0:005 for 1000 F vs. baseline values. +P ¼ 0:003 for 1000 F vs. 500 F and 0 F at 3 months
after randomization. ++P ¼ 0:009 for 1000 F vs. 500 F and 0 F at 6 months after randomization.
M.A. Martı´nez-Garcı´a et al.1630bronchiectasis. In agreement with the clinical
improvement observed, the questionnaire scale
affording the greatest improvement and critically
conditioning improvement in overall patient score
was the symptoms scale. As regards the activity and
impact scales of the questionnaire—more exten-
sively determined by parameters such as dyspnea,
functional variables or psychological factors—a
statistically significant late improvement in the
former was only obtained in the group treated with
PF 1000 mg. However, the clinical significance of
this improvement is difficult to evaluate, since no
reference values are described for minimum rele-
vant changes on this scale. According to our results,
at least one out of every two patients (NNT)
treated with 1000 PF showed significant improve-
ments in HRQoL.
In two well-conducted studies, Tsang et al.
reported that FP 1000 mg reduces 24-h sputum
volume, leukocyte density and several inflamma-
tory cytokines of sputum (Interleukin-8, leuko-
triene-B4 and interleukin-1b), without modifying
bacterial density in patients with bronchiecta-
sis.11,13 In this same sense, Elborn et al.12 reported
that 6-week treatment with high doses of beclo-methasone produces significant reductions in spu-
tum volume. Accordingly, in our study, the
reduction in daily sputum production together with
the improvement of dyspnea and the increase in
days without cough implied that the group of
patients treated with high-dose FP retained better
clinical control—as supported by the significantly
lesser need for short-acting b2 agonists early from
baseline. In contrast, treatment with FP 500 mg
daily only yielded a moderate, late reduction in
both daily sputum amount and the dose of short-
acting b2 agonist medication.
Similarly to COPD26 and in some studies of
patients with bronchiectasis,11–13 treatment with
high doses of inhaled steroids did not lead to
significant improvement in the functional para-
meters. However, it must be noted that in our
series, after 1 month of treatment with FP 1000 mg,
FEV1 increased 64ml from baseline. This effect
persisted after 6 months. However, we found a
38-ml reduction in the group without steroid
treatment at 6 months. While not statistically
significant, this observation could indicate slowing
of the long-term decline in FEV1 among treated
patients, supported by the fact that most patients
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mean annual loss of 50ml in FEV1
8 Longer term
studies would be needed to confirm this, however.
Another conclusion that can be drawn from our
study, in line with the recent observations of Tsang
et al.13 is that inhaled steroids do not appear to
reduce the number of acute exacerbations in these
patients—though no increase is seen in chronic
colonization by potentially pathogenic organisms
such as PA or HI. No changes were seen in the
severity of acute exacerbations considering the
lack of changes in the number of hospital admis-
sions, visits to emergency rooms and the number of
cycles of antibiotics or oral steroids prescribed in
the three treatment groups. In this context, the
behavior of bronchiectasis is different from that
seen in asthma and severe COPD—these being
disorders where a reduction in the number of
exacerbations has been described with inhaled
steroids therapy.26,27 It is likely that the explana-
tion for this discrepancy is the inability of steroids
to eradicate organisms more frequently causing
acute exacerbations in these patients, such as PA or
HI which are strongly attached to a structurally
altered bronchial mucosa—causing chronic inflam-
mation that proves difficult to resolve without
eliminating the organism.28
It is important to mention that special care was
taken to exclude patients with suspected bronchial
asthma according to the definition of the GINA,
since corticosteroids are known to be the most
effective therapy available for asthma.15 However,
we decided not to exclude patients with COPD, due
to the great difficulty sometimes found in differ-
entiating smokers with bronchiectasis who more-
over also present COPD from those who do not have
COPD. In any case, since some studies have shown a
certain positive effect of inhaled steroids upon
some clinical and functional parameters in patients
with advanced COPD,10,11 randomization of treat-
ment was stratified for prior smoking habit as
measured in pack-years.26,29
Our study has a number of limitations that should
be commented. Firstly, no placebo group was
included, due to the lack of availability of placebo
in our center. In an attempt to partly make up for
this deficiency, we introduced an untreated patient
group and a group with an intermediate dose to be
used as control for assessing efficacy over time of
the higher daily drug dose (PF 1000 mg). In addition,
the study was conducted on a partially double-blind
basis, since both the patient and the investigators
were aware of whether or not inhalatory steroid
treatment had been prescribed, but they did
not know the effective doses involved (500 vs.
1000 mg/day).In conclusion, we consider that despite a lack of
improvement in pulmonary function and the num-
ber or severity of acute exacerbations, patients
with non-CF steady-state bronchiectasis could
benefit from treatment with inhaled FP 500 mg
bid, due to the significant reduction in the amount
of sputum produced, the improvement in dyspnea,
and the increase in days without cough—thus
allowing for lesser use of rescue medication and
clinically significant improvement in HRQoL.Acknowledgements
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